HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3)

Archivio Italiano di Urologia e Andrologia

Volumn 85, Issue 2, 2013, Pages 73-77

  Bongiovanni, Luca ^a   Arena, Vincenzo ^b   Vecchio, Fabio Maria ^b   Racioppi, Marco ^a   Bassi, Pierfrancesco ^a   Pierconti, Francesco ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bladder cancer; HER 2 expression; Prognostic marker; T1G3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; STAINING; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; BLADDER TUMOR; CHEMISTRY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84883522690     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: 10.4081/aiua.2013.2.73     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Malkowicz SB, Van Poppel H, Mickisch G, et al. Muscle-invasive urothelial carcinoma of the bladder. Urology. 2007; 69(1 Suppl): 3-16. (Pubitemid 46186483)
3. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997; 158: 62-67. (Pubitemid 27251595)
4. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010; 57: 60-70.
5. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19:3159.
6. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61(suppl.2):1.
7. Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer. 1992; 70: 2493
8. Kruger S, Weitsch G, Buttner H, et al. Overexpression of c-erbB- 2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol. 2002; 21:981.
9. Lipponen P, Eskelinen M, Syrjanen S, et al. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991; 20:238.
10. Kolla SB, Seth A, Singh MK, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol. 2008; 40:3219.
11. Bolenz C, Shariat S, Karakiewicz P, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU 2010; 106:1216.
12. Mellon JK, Lunec J, Wright C, et al. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol. 1996; 155:321.
13. Jimenez RE, Hussain M, Bianco FJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001; 7:2440.
14. Liedberg F, Anderson H, Chebil G, et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol. 2008; 26:17.
15. Chow NH, Chan SH, Tzai T, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 2001; 7:1957.
16. Kassouf W, Black PC, Tuziak T, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008; 179:353.
17. Lonn U, Lonn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res. 1995; 1:1189.
18. Bellmunt J, Albiol S, Suarez C, et al. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol. 2009; 69:211.
19. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008; 18:1.
20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118.
21. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675. (Pubitemid 32120143)
22. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscleinvasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59: 1009-1018.
23. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178: 2314-2330. (Pubitemid 350080987)
24. Chang SS, Cookson MS. Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology. 2005; 66: 917-922. (Pubitemid 41587132)
25. Zhau HE, Zhang X, von Eschenbach AC, et al. Amplification and expression of the c-erb B2/neu protooncogene in human bladder cancer. Mol Carcinog. 1990; 3: 254-25.
26. Gandour Edward R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002; 95:1009.
27. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118.
28. Chakraverti A, Winter K, Wu Cl, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005; 62:209.
29. Underwood M, Bartlett J, Reeves J, et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res. 1995; 55:2422.
30. Laé M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancerwith a standardized methodology: result in 1005 patients. Ann Oncol. 2010; 21:815.